Research ArticleArticle
Effects of Rituximab and Infliximab Treatment on Carboxypeptidase B and Its Substrates in RA Synovium
Stefan Edginton, Carol Hitchon, Warren Froese and Hani El-Gabalawy
The Journal of Rheumatology March 2016, jrheum.150869; DOI: https://doi.org/10.3899/jrheum.150869
Stefan Edginton
From the Department of Internal Medicine and Department of Surgery, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. Supported by the Canadian Arthritis Network (Ethics:B2003:106; Protocol: P04055). Rituximab supplied by Roche Canada (ML25014 Synovial Biopsy Study). Infliximab supplied by Schering Canada Inc. The Canadian Arthritis Network National Centres of Excellence, in partnership with Roche Canada and Schering Canada, financially supported these studies. S. Edginton, BSc, Department of Internal Medicine, University of Manitoba; C.A. Hitchon, MD, FRCPC, Department of Internal Medicine, University of Manitoba; W. Froese*, MD, FRCSC, Department of Surgery, University of Manitoba; H. El-Gabalawy, MD, FRCPC, Department of Internal Medicine, University of Manitoba. * Author died October 17, 2014. Address correspondence to S. Edginton, University of Manitoba, Rheumatology, RR149, 800 Sherbrook St., Winnipeg, Manitoba R3A 1M4, Canada. E-mail: stefanedginton@gmail.com. Accepted for publication January 7, 2016.
Carol Hitchon
From the Department of Internal Medicine and Department of Surgery, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. Supported by the Canadian Arthritis Network (Ethics:B2003:106; Protocol: P04055). Rituximab supplied by Roche Canada (ML25014 Synovial Biopsy Study). Infliximab supplied by Schering Canada Inc. The Canadian Arthritis Network National Centres of Excellence, in partnership with Roche Canada and Schering Canada, financially supported these studies. S. Edginton, BSc, Department of Internal Medicine, University of Manitoba; C.A. Hitchon, MD, FRCPC, Department of Internal Medicine, University of Manitoba; W. Froese*, MD, FRCSC, Department of Surgery, University of Manitoba; H. El-Gabalawy, MD, FRCPC, Department of Internal Medicine, University of Manitoba. * Author died October 17, 2014. Address correspondence to S. Edginton, University of Manitoba, Rheumatology, RR149, 800 Sherbrook St., Winnipeg, Manitoba R3A 1M4, Canada. E-mail: stefanedginton@gmail.com. Accepted for publication January 7, 2016.
Warren Froese
From the Department of Internal Medicine and Department of Surgery, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. Supported by the Canadian Arthritis Network (Ethics:B2003:106; Protocol: P04055). Rituximab supplied by Roche Canada (ML25014 Synovial Biopsy Study). Infliximab supplied by Schering Canada Inc. The Canadian Arthritis Network National Centres of Excellence, in partnership with Roche Canada and Schering Canada, financially supported these studies. S. Edginton, BSc, Department of Internal Medicine, University of Manitoba; C.A. Hitchon, MD, FRCPC, Department of Internal Medicine, University of Manitoba; W. Froese*, MD, FRCSC, Department of Surgery, University of Manitoba; H. El-Gabalawy, MD, FRCPC, Department of Internal Medicine, University of Manitoba. * Author died October 17, 2014. Address correspondence to S. Edginton, University of Manitoba, Rheumatology, RR149, 800 Sherbrook St., Winnipeg, Manitoba R3A 1M4, Canada. E-mail: stefanedginton@gmail.com. Accepted for publication January 7, 2016.
Hani El-Gabalawy
From the Department of Internal Medicine and Department of Surgery, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. Supported by the Canadian Arthritis Network (Ethics:B2003:106; Protocol: P04055). Rituximab supplied by Roche Canada (ML25014 Synovial Biopsy Study). Infliximab supplied by Schering Canada Inc. The Canadian Arthritis Network National Centres of Excellence, in partnership with Roche Canada and Schering Canada, financially supported these studies. S. Edginton, BSc, Department of Internal Medicine, University of Manitoba; C.A. Hitchon, MD, FRCPC, Department of Internal Medicine, University of Manitoba; W. Froese*, MD, FRCSC, Department of Surgery, University of Manitoba; H. El-Gabalawy, MD, FRCPC, Department of Internal Medicine, University of Manitoba. * Author died October 17, 2014. Address correspondence to S. Edginton, University of Manitoba, Rheumatology, RR149, 800 Sherbrook St., Winnipeg, Manitoba R3A 1M4, Canada. E-mail: stefanedginton@gmail.com. Accepted for publication January 7, 2016.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Effects of Rituximab and Infliximab Treatment on Carboxypeptidase B and Its Substrates in RA Synovium
Stefan Edginton, Carol Hitchon, Warren Froese, Hani El-Gabalawy
The Journal of Rheumatology Mar 2016, jrheum.150869; DOI: 10.3899/jrheum.150869